MG
ABBV icon

Marex Group’s AbbVie ABBV Stock Holding History

Marex Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Sell
5,599
-303,395
-98% -$65.3M 0.01% 438
2026
Q1 		$67.2M Buy
308,994
+307,718
+24,116% +$68.3M 0.42% 67
2025
Q4 		$292K Sell
1,276
-185
-13% -$42.1K ﹤0.01% 714
2025
Q3 		$338K Sell
1,461
-4,453
-75% -$907K ﹤0.01% 596
2025
Q2 		$1.1M Buy
5,914
+2,550
+76% +$474K 0.01% 277
2025
Q1 		$705K Sell
3,364
-1,047
-24% -$204K 0.01% 277
2024
Q4 		$784K Sell
4,411
-5,013
-53% -$922K 0.01% 276
2024
Q3 		$1.86M Buy
9,424
+6,362
+208% +$1.19M 0.04% 158
2024
Q2 		$525K Buy
3,062
+1,329
+77% +$220K 0.01% 297
2024
Q1 		$316K Buy
1,733
+166
+11% +$28.6K 0.01% 315
2023
Q4 		$243K Buy
+1,567
New +$228K 0.01% 429
2023
Q2 		– Sell
-1,681
Closed -$268K – 225
2023
Q1 		$268K Sell
1,681
-9,813
-85% -$1.5M 0.04% 211
2022
Q4 		$1.86M Buy
+11,494
New +$1.76M 0.26% 78

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Marex Group's ABBV Position: Q2 2026 in Review

Marex Group reduced its AbbVie (ABBV) stake by 98% in Q2 2026, selling an estimated $65.3M and leaving 5,599 shares worth $1.41M. The position accounts for 0.01% of the portfolio, ranked #438.

Marex Group first reported a position in ABBV in Q4 2022 and has held it in 13 quarters since. The position peaked at $67.2M in Q1 2026. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Marex Group held 5,599 shares of AbbVie worth $1.41M as of Q2 2026.
  • Marex Group sold 303,395 AbbVie shares in Q2 2026, an estimated $65.3M.
  • AbbVie made up 0.01% of Marex Group's portfolio in Q2 2026, its #438 holding.
  • Marex Group first reported a position in AbbVie in Q4 2022 and has held it in 13 quarters since.
  • Marex Group's AbbVie position peaked at $67.2M in Q1 2026.
  • 4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.